Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

ClinicalTrials.gov ID: NCT01495988

Public ClinicalTrials.gov record NCT01495988. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase 2 clinical trial randomizes patients with BRAF mutant melanoma to either (1) standard of care (SOC) - BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib; or, (2) SOC plus bevacizumab, an anti-VEGF antibody that suppresses new blood vessel formation and can stimulate the immune system. Previous clinical studies in melanoma have shown that bevacizumab may improve clinical benefit (progression free survival) if combined with ipilimumab or abraxane. Preclinical studies suggest that VEGF increase plays a role in resistance to BRAF inhibitors. This randomized study will ask whether the addition of bevacizumab to targeted therapy SOC in BRAF mutant melanoma can improve response rates and clinical benefit. Patients may have received no therapy for advanced disease or up to 2 prior therapies, excluding BRAF and MEK inhibitors.

Study identification

NCT ID: NCT01495988
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Melanoma Research Foundation Breakthrough Consortium; Other
Enrollment: 10 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 2013 (Type not available)
Primary completion: Jan 2016 (Actual)
Completion: Jun 2016 (Actual)
Last update posted: Oct 24, 2017

2013 – 2016

United States locations

U.S. sites: 14
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
The Angeles Clinic	Los Angeles	California	90025	—
University of Colorado Cancer Center	Aurora	Colorado	80045	—
Georgetown Lombardi Comprehensive Cancer Center	Washington D.C.	District of Columbia	20007	—
Washington Cancer Institute at MedStar Washington Hospital Center	Washington D.C.	District of Columbia	20010	—
Harry and Jeannette Weinberg Cancer Institute at Franklin Square	Baltimore	Maryland	21237	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Beth Israel Deaconess Medical Center (BIDMC)	Boston	Massachusetts	02215	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
NYU Clinical Cancer Center	New York	New York	10016	—
Columbia University Medical Center	New York	New York	10032	—
OSU Comprehensive Cancer Center	Columbus	Ohio	43210	—
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15232	—
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37232	—
University of Washington Medical Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01495988, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 24, 2017 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01495988 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →